Xencor, Inc. (NASDAQ:XNCR) Receives $24.25 Consensus PT from Brokerages

Xencor, Inc. (NASDAQ:XNCR) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $24.25.

A number of equities analysts recently issued reports on XNCR shares. Wall Street Zen lowered Xencor from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 9th. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Truist Financial cut their price objective on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Finally, JPMorgan Chase & Co. increased their price target on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th.

Institutional Investors Weigh In On Xencor

Several hedge funds have recently added to or reduced their stakes in XNCR. Vanguard Group Inc. lifted its holdings in shares of Xencor by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock valued at $109,703,000 after buying an additional 61,692 shares during the period. BVF Inc. IL increased its holdings in shares of Xencor by 160.3% during the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after purchasing an additional 4,393,579 shares in the last quarter. RTW Investments LP increased its holdings in shares of Xencor by 8.9% during the 4th quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock valued at $103,763,000 after purchasing an additional 556,407 shares in the last quarter. State Street Corp lifted its stake in shares of Xencor by 22.7% in the 4th quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after purchasing an additional 833,423 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Xencor by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 1,752,918 shares of the biopharmaceutical company’s stock worth $26,842,000 after acquiring an additional 24,093 shares during the period.

Xencor Trading Up 0.2%

NASDAQ:XNCR opened at $14.98 on Monday. Xencor has a twelve month low of $6.92 and a twelve month high of $18.69. The company has a market cap of $1.11 billion, a PE ratio of -6.54 and a beta of 0.86. The company’s 50 day moving average is $13.07 and its two-hundred day moving average is $12.76.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). The company had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The company’s quarterly revenue was down 86.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.66) EPS. As a group, analysts expect that Xencor will post -3.88 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.